^
    PanTracer™ Tissue + HRD is a next-generation, tissue-based comprehensive genomic profiling (CGP) test that integrates homologous recombination deficiency (HRD) assessment - combining genomic insights from over 500 genes with HRD analysis specifically tailored for ovarian cancer.
    Cancer:
    Ovarian Cancer
    Gene:
    BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), HRD (Homologous Recombination Deficiency)
    Method:
    RNA/DNA-based molecular screening test